Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 3Phase 2/3 2Phase 1/2 2Phase NA 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 58Lung Neoplasms 13Colorectal Neoplasms 11Neoplasms 8Mesothelioma, Malignant 7Mesothelioma 7Meningeal Carcinomatosis 7Neoplasm Metastasis 6Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Melanoma 4Stomach Neoplasms 3Pancreatic Neoplasms 3Gastrointestinal Neoplasms 3Carcinoma, Transitional Cell 3Advanced Solid Tumors 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms by Site 2NSCLC 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Carcinoma 2Advanced Solid Tumor 2Urologic Neoplasms 1Solitary Fibrous Tumor, Pleural 1Rectal Neoplasms 1

Interventions

Pemetrexed 2Carboplatin 2sulindac sulfone 1pembrolizumab 1nimotuzumab 1aflutinib 1Clinical Trials, Phase I as Topic 1BID protein, human 1Antigens 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × NSCLC × Pemetrexed × Clear all
NCT05636267 2026-03-09

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

Akeso

Phase 1/2 Terminated
59 enrolled
Thoracic

NSCLC

NCT03562871 2022-04-21

IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC

IO Biotech

Phase 1/2 Completed
109 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡